BioMarin Pharmaceutical BMRN shares are trading higher on Wednesday, after Bank of Americamaintained its Buy rating on the stock and raised the price target from $120 to $130 per share.
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently.
BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA).
BioMarin shares are trading up 1.73% at $106.91 at time of publication on Wednesday. The stock has a 52-week high of $112.57 and a 52-week low of $62.88.
Related Links:
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
